Milestones

Won the 26th Symbol of National Quality (SNQ) Mark and National Biotechnology & Medical Care Quality Award.
Signed an R&D agreement with hospitals in Thailand.
Completed of patient enrollment for HCC(Liver Cancer) clinical trial.
Patent application for LuKas-T and cryogenic technology.
The HNSCC clinical trial moved forward to phase II.
Applied for approval letter for Technology Enterprises.
Applied for IPO listing.

Won the 25th Symbol of National Quality (SNQ) Mark and National Biotechnology & Medical Care Quality Award.
Large scale enrollment for liver cancer clinical trial.
Initiated Chimeric Antigen Receptor (CAR)-related preclinical trials.
Recognized by Life Sciences Review Magazine as one of Asia's top 10 clinical trial biomedical companies.

Won the 24th Symbol of National Quality (SNQ) Mark and National Biotechnology & Medical Care Quality Award.
Completed the application process for the Phase II clinical trial of liver cancer in Taiwan under the U.S. ODD and IND programs.
Applied for a clinical trial license from the Ministry of Health and Welfare in Taiwan and collaborated with 13 medical centers and large hospitals in Taiwan for clinical trials (cases being enrolled continuously).
Established collaboration with Pan Chiao Chung Hsing Hospital, Chi Mei Hospital Liouying, Shin Kong Hospital, and Far Eastern Memorial Hospital under the Administrative Regulation.
Awarded the 4th Golden Ship Award for Innovative Services by the General Chamber of Commerce of the Republic of China.
Won the DEMO DAY Award from the Tai-Fu Startup Association.
FreshO2 partnered with Arata (JP-2733, Japan’s largest wholesaler in the field of daily goods and cosmetics) to enter the Japanese cosmetics market.

Lukas "Cell Lab" obtained GTP approval as a cell processing unit (CPU) from the Ministry of Health and Welfare, with approval No.: TP109C019.
Lukas's LuLym-T passed the FDA's investigational new drug (IND) review for Phase II clinical trials under orphan drug designation (ODD) for liver cancer.
Launched a "Circulating Tumor Cell (CTC) Test" service.
Established collaboration with Hualien Tzu Chi Hospital under the ”Regulations of Special Medical Technigues”

Obtained FDA orphan drug designation and pre-IND status for liver cancer in U.S.
Public offering and listing on the Emerging Stock Market (Code: 6814).

Constructed a national-level GTP laboratory in Xizhi, now fully operational.
Applied for ”Regulations of Special Medical Technigues” for clinical application of T cells with several hospital.

Collaborated with Taipei Veterans General Hospital (TVGH) for the first clinical trial of T-cell combined chemo-radiotherapy in Taiwan.
Passed orphan drug review in the U.S. and obtained FDA clinical approval.
Developed technology for culturing dendritic cells, natural killer cells, and novel tumor-antigen T cells to complement T-cell therapeutics.
Established FreshO2, a biotech cosmetic brand.

Completed technology transfer with Japan for the first clinical trial of T cells in Taiwan.

Established research collaboration with National Cancer Center Japan and Lymphotec Inc.

Established Jia-Mih Enterprise Co., Ltd., with a registered capital of NT$500,000.